Advertisement

Topics

Cardiome shaken by FDA no-go on heart drug refiling

05:36 EDT 22 Aug 2017 | BioPharmaDive

The Canadian drugmaker's stock fell by almost a quarter after disclosing the data package for Brinavess wasn't sufficient for a resubmitted New Drug Application.

Original Article: Cardiome shaken by FDA no-go on heart drug refiling

NEXT ARTICLE

More From BioPortfolio on "Cardiome shaken by FDA no-go on heart drug refiling"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...